Cytokeratin 14/16 (S5) polyclonal Antibody | BS1200

Cytokeratin 14/16 (S5) polyclonal Antibody | BS1200 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Rat,Mouse

Application: WB

Application Range: WB: 1:500~1:1000

Background: In Bowen’s disease, the characteristic malignancy of the epidermis exhibits distinct expression patterns of Cytokeratin 14. Mutations in the gene encoding human Cytokeratin 14 lead to epidermolysis bullosa simplex, an inheritied skin disorder characterized by skin blistering due to basal keratinocyte fragility.Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in noninvasive breast carcinomas and normal breast tissue. Mutations in the Cytokeratin 16 gene cause various diseases, including pachyonychia congenita type 1 (PC1), nonepidermolytic palmoplantar keratoderma (NEPPK) and unilateral palmoplantar verrucous nevus (UPVN) .

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Cytokeratin 14/16 (S5) polyclonal Antibody detects endogenous levels of Cytokeratin 14 and Cytokeratin 16 protein.

Molecular Weight: ~ 60 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Keratin, type I cytoskeletal 14; Cytokeratin-14; Short name=CK-14; Keratin-14; Short name=K14; KRT14; CK-14; CK 14; CK14; Cytokeratin-14; Cytokeratin 14; Cytokeratin14; Keratin, type I cytoskeletal 16; Cytokeratin-16; Short name=CK-16; Keratin-16; Short name=K16; KRT16; KRT16A; CK-16; CK 16; CK16; Cytokeratin-16; Cytokeratin 16; Cytokeratin16;

Immunogen: Synthetic peptide, corresponding to the N-terminus of Human Cytokeratin 14

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: